drugset / Trial / NCT05175352
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Timeline
- Start
- 2022-06-07
- Primary completion
- 2024-10-11
- Completion
- 2024-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cendakimab | Monoclonal antibody | — | — |